Denali Therapeutics (DNLI) News Today $14.20 +0.39 (+2.82%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$14.19 -0.01 (-0.07%) As of 03/27/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Denali Therapeutics (NASDAQ:DNLI) Sets New 1-Year Low - Here's WhyDenali Therapeutics (NASDAQ:DNLI) Hits New 52-Week Low - Here's What HappenedMarch 27 at 10:49 AM | marketbeat.comPier Capital LLC Acquires 164,237 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)Pier Capital LLC lifted its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 97.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 332,319 shares of the company's stock after purchasing an additionMarch 26 at 6:38 AM | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by BrokeragesDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has received an average rating of "Moderate Buy" from the eighteen brokerages that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation, fifteen have given a buy recommMarch 26 at 2:23 AM | marketbeat.comFox Run Management L.L.C. Makes New $788,000 Investment in Denali Therapeutics Inc. (NASDAQ:DNLI)Fox Run Management L.L.C. purchased a new position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 38,668 shares of the company's stock, valued atMarch 25 at 5:19 AM | marketbeat.comProficio Capital Partners LLC Makes New $514,000 Investment in Denali Therapeutics Inc. (NASDAQ:DNLI)Proficio Capital Partners LLC purchased a new position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,210 shares of the companMarch 24, 2025 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Shares Purchased by Intech Investment Management LLCIntech Investment Management LLC boosted its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 60.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 47,401 shares of the company's stock after acquiringMarch 23, 2025 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Holdings Boosted by Yiheng Capital Management L.P.Yiheng Capital Management L.P. lifted its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 16.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 700,098 shares of the company's stock after purchasinMarch 22, 2025 | marketbeat.com19,782 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Acquired by Wealthfront Advisers LLCWealthfront Advisers LLC bought a new position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 19,782 shares of the company's stock, valued at approximately $403,000.March 17, 2025 | marketbeat.comFY2027 Earnings Estimate for DNLI Issued By Zacks ResearchDenali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities research analysts at Zacks Research issued their FY2027 earnings per share estimates for Denali Therapeutics in a research note issued on Thursday, March 13th. Zacks Research analyst A. Chakraborty forecasts that the company will posMarch 17, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Trading Down 8.9% Following Analyst DowngradeDenali Therapeutics (NASDAQ:DNLI) Shares Down 8.9% on Analyst DowngradeMarch 11, 2025 | marketbeat.comBank of America Lowers Denali Therapeutics (NASDAQ:DNLI) Price Target to $28.00Bank of America cut their price objective on Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a report on Monday.March 11, 2025 | marketbeat.comDenali Therapeutics (DNLI) Receives a Buy from Bank of America SecuritiesMarch 10, 2025 | markets.businessinsider.comBank of New York Mellon Corp Decreases Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)Bank of New York Mellon Corp decreased its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 6.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,242,987 shares of the company's stock after selling 87,364 shares duriMarch 10, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Now Covered by Analysts at Morgan StanleyMorgan Stanley initiated coverage on Denali Therapeutics in a report on Friday. They issued an "overweight" rating and a $33.00 price target for the company.March 8, 2025 | marketbeat.comQ2 EPS Estimates for Denali Therapeutics Cut by B. RileyDenali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Investment analysts at B. Riley lowered their Q2 2025 earnings per share (EPS) estimates for shares of Denali Therapeutics in a research report issued on Wednesday, March 5th. B. Riley analyst M. Mamtani now anticipates that the company willMarch 8, 2025 | marketbeat.comDenali Therapeutics assumed with an Overweight at Morgan StanleyMarch 7, 2025 | markets.businessinsider.comWhat is B. Riley's Estimate for DNLI FY2029 Earnings?Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Research analysts at B. Riley issued their FY2029 EPS estimates for shares of Denali Therapeutics in a research report issued on Wednesday, March 5th. B. Riley analyst M. Mamtani expects that the company will post earnings per share of $0.87March 7, 2025 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Shares Sold by Candriam S.C.A.Candriam S.C.A. cut its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 11.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 832,977 shares of the company's stock after selling 109,181March 7, 2025 | marketbeat.comDenali Therapeutics' (DNLI) "Buy" Rating Reaffirmed at B. RileyB. Riley restated a "buy" rating and set a $35.00 target price (down previously from $38.00) on shares of Denali Therapeutics in a research report on Wednesday.March 6, 2025 | marketbeat.comDenali Therapeutics Enters Oversold Territory (DNLI)March 5, 2025 | nasdaq.comDenali Therapeutics discontinues active treatment extension in eIF2B Regimen GMarch 5, 2025 | markets.businessinsider.comDenali Therapeutics price target lowered to $35 from $38 at B. RileyMarch 5, 2025 | markets.businessinsider.comDenali Therapeutics (NASDAQ:DNLI) Hits New 52-Week Low on Analyst DowngradeDenali Therapeutics (NASDAQ:DNLI) Hits New 52-Week Low Following Analyst DowngradeMarch 5, 2025 | marketbeat.comFisher Asset Management LLC Has $16.15 Million Position in Denali Therapeutics Inc. (NASDAQ:DNLI)Fisher Asset Management LLC raised its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 44.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 792,499 shares of the company's stock after buying anMarch 4, 2025 | marketbeat.comIs Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025?March 3, 2025 | insidermonkey.comOppenheimer Lowers Denali Therapeutics (NASDAQ:DNLI) Price Target to $42.00Oppenheimer reduced their target price on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating on the stock in a research note on Monday.March 3, 2025 | marketbeat.comDenali Therapeutics price target lowered to $42 from $50 at OppenheimerMarch 3, 2025 | markets.businessinsider.comWhat is HC Wainwright's Forecast for DNLI Q1 Earnings?Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Denali Therapeutics in a research report issued on Friday, February 28th. HC Wainwright analyst A. Fein anticipates that the company will post earnings perMarch 3, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Stock Price Down 6.5% - Should You Sell?Denali Therapeutics (NASDAQ:DNLI) Shares Down 6.5% - Should You Sell?March 1, 2025 | marketbeat.comWilliam Blair Reiterates "Outperform" Rating for Denali Therapeutics (NASDAQ:DNLI)William Blair reaffirmed an "outperform" rating on shares of Denali Therapeutics in a report on Friday.March 1, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Price Target Raised to $87.00HC Wainwright boosted their target price on Denali Therapeutics from $80.00 to $87.00 and gave the stock a "buy" rating in a research report on Friday.March 1, 2025 | marketbeat.comY Intercept Hong Kong Ltd Has $734,000 Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)Y Intercept Hong Kong Ltd raised its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 160.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 36,006 shares of the company's sMarch 1, 2025 | marketbeat.comDenali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of "Moderate Buy" by BrokeragesDenali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has received an average rating of "Moderate Buy" from the fifteen ratings firms that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating anMarch 1, 2025 | marketbeat.comDenali Therapeutics price target lowered to $32 from $33 at WedbushMarch 1, 2025 | markets.businessinsider.comDenali Therapeutics (DNLI) Receives a Buy from Stifel NicolausMarch 1, 2025 | markets.businessinsider.comDenali Therapeutics (NASDAQ:DNLI) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPSDenali Therapeutics (NASDAQ:DNLI - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.08.February 28, 2025 | marketbeat.comTD Cowen Keeps Their Buy Rating on Denali Therapeutics (DNLI)February 28, 2025 | markets.businessinsider.comDenali Therapeutics reports Q4 EPS (67c), consensus (85c)February 27, 2025 | markets.businessinsider.comDenali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business HighlightsFebruary 27, 2025 | globenewswire.comPrincipal Financial Group Inc. Sells 107,513 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)Principal Financial Group Inc. lowered its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 8.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,130,963 shares ofFebruary 24, 2025 | marketbeat.comEmpowered Funds LLC Takes Position in Denali Therapeutics Inc. (NASDAQ:DNLI)Empowered Funds LLC acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 18,587 shares of the company's stock, valueFebruary 21, 2025 | marketbeat.comDenali Therapeutics (DNLI) to Release Quarterly Earnings on TuesdayDenali Therapeutics (NASDAQ:DNLI) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comBaillie Gifford & Co. Cuts Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)Baillie Gifford & Co. trimmed its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 7.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 12,313,931 shares of the company's stock afterFebruary 17, 2025 | marketbeat.comDeutsche Bank Initiates Coverage of Denali Therapeutics (DNLI) with Buy RecommendationFebruary 12, 2025 | msn.comDeutsche Bank sets $31 target for Denali Therapeutics stockFebruary 11, 2025 | msn.comDenali Therapeutics initiated with a Buy at Deutsche BankFebruary 11, 2025 | markets.businessinsider.comDenali Therapeutics (NASDAQ:DNLI) Shares Gap Up - Time to Buy?Denali Therapeutics (NASDAQ:DNLI) Shares Gap Up - Here's WhyFebruary 11, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Coverage Initiated by Analysts at Deutsche Bank AktiengesellschaftDeutsche Bank Aktiengesellschaft began coverage on Denali Therapeutics in a research note on Tuesday. They set a "buy" rating and a $31.00 price objective on the stock.February 11, 2025 | marketbeat.comDenali Therapeutics (NASDAQ:DNLI) Stock Price Down 4.9% - Here's What HappenedDenali Therapeutics (NASDAQ:DNLI) Trading Down 4.9% - Time to Sell?February 10, 2025 | marketbeat.comStifel maintains Buy on Denali Therapeutics, $37 targetFebruary 10, 2025 | msn.com Remove Ads Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address DNLI Media Mentions By Week DNLI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNLI News Sentiment▼1.310.78▲Average Medical News Sentiment DNLI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNLI Articles This Week▼85▲DNLI Articles Average Week Remove Ads Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Today Sarepta Therapeutics News Today Revolution Medicines News Today BridgeBio Pharma News Today Lantheus News Today TG Therapeutics News Today Legend Biotech News Today Axsome Therapeutics News Today Telix Pharmaceuticals Limited American Depositary Shares News Today Blueprint Medicines News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DNLI) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DNLI Stock Free DNLI Stock Alerts